{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:11:40Z","timestamp":1788970300794,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100031694","name":"Sir Charles Gairdner Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031694","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04560-w","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:30:06Z","timestamp":1788967806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fibroblast growth factor receptor 3 (FGFR3) alterations and response to immune checkpoint inhibition in metastatic urothelial carcinoma: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0673-6804","authenticated-orcid":false,"given":"Oliver","family":"Oey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wynne","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Febriyanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisrina Nur","family":"Fatiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qonita Jayanti","family":"Wijayatno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"12","key":"4560_CR1","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","volume":"27","author":"T Powles","year":"2021","unstructured":"Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJ, Ching KA, et al. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med. 2021;27(12):2200\u201311. https:\/\/doi.org\/10.1038\/s41591-021-01579-0.","journal-title":"Nat Med"},{"issue":"1","key":"4560_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","volume":"35","author":"AO Siefker-Radtke","year":"2024","unstructured":"Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, \u00d6zg\u00fcro\u011flu M, et al. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. Ann Oncol. 2024;35(1):107\u201318. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.003.","journal-title":"Ann Oncol"},{"issue":"19","key":"4560_CR3","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-20-0729","volume":"26","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S, et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275. Clin Cancer Res. 2020;26(19):5120\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0729.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4560_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0312-8.","journal-title":"Nat Genet"},{"issue":"1","key":"4560_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102284","volume":"23","author":"R Talukder","year":"2025","unstructured":"Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, et al. Clinical outcomes with immune checkpoint inhibitors in patients with FGFR2\/3, MTAP or ERBB2 genomic alterations in advanced urothelial carcinoma. Clin Genitourin Cancer. 2025;23(1):102284. https:\/\/doi.org\/10.1016\/j.clgc.2024.102284.","journal-title":"Clin Genitourin Cancer"},{"key":"4560_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006643","volume":"11","author":"Y Song","year":"2023","unstructured":"Song Y, Peng Y, Qin C, Wang Y, Yang W, Du Y, et al. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. J Immunother Cancer. 2023;11:e006643. https:\/\/doi.org\/10.1136\/jitc-2022-006643.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4560_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","volume":"76","author":"L Wang","year":"2019","unstructured":"Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, et al. Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. 2019;76(5):599\u2013603. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.025.","journal-title":"Eur Urol"},{"issue":"9","key":"4560_CR8","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real-world experience. Br J Cancer. 2021;125(9):1251\u201360. https:\/\/doi.org\/10.1038\/s41416-021-01488-6.","journal-title":"Br J Cancer"},{"key":"4560_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, et al. The impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol Cancer. 2023;22:185. https:\/\/doi.org\/10.1186\/s12943-023-01897-6.","journal-title":"Mol Cancer"},{"issue":"6","key":"4560_CR10","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.euo.2024.01.013","volume":"7","author":"K Shigeta","year":"2024","unstructured":"Shigeta K, Matsumoto K, Kitaoka S, Omura M, Umeda K, Arita Y, et al. Profiling fibroblast growth factor receptor 3 expression based on the immune microenvironment in upper tract urothelial carcinoma. Eur Urol Oncol. 2024;7(6):1338\u201349. https:\/\/doi.org\/10.1016\/j.euo.2024.01.013.","journal-title":"Eur Urol Oncol"},{"key":"4560_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.euros.2022.11.001","volume":"47","author":"A Rezazadeh Kalebasty","year":"2023","unstructured":"Rezazadeh Kalebasty A, Benjamin DJ, Loriot Y, Papantoniou D, Siefker-Radtke AO, Necchi A, et al. Outcomes of patients with advanced urothelial carcinoma after anti-programmed death-(ligand) 1 therapy by fibroblast growth factor receptor gene alteration status: an observational study. Eur Urol Open Sci. 2023;47:48\u201357. https:\/\/doi.org\/10.1016\/j.euros.2022.11.001.","journal-title":"Eur Urol Open Sci"},{"issue":"22","key":"4560_CR12","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","volume":"29","author":"BJ Guercio","year":"2023","unstructured":"Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, et al. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin Cancer Res. 2023;29(22):4586\u201395. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1283.","journal-title":"Clin Cancer Res"},{"key":"4560_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.urology.2021.05.053","volume":"156","author":"KH Tully","year":"2021","unstructured":"Tully KH, Jutte H, Wirtz RM, Jarczyk J, Santiago-Walker A, Zengerling F, et al. Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer undergoing checkpoint inhibitor therapy. Urology. 2021;156:230\u20137. https:\/\/doi.org\/10.1016\/j.urology.2021.05.053.","journal-title":"Urology"},{"issue":"1","key":"4560_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.clgc.2022.11.007","volume":"21","author":"NS Chawla","year":"2023","unstructured":"Chawla NS, Sayegh N, Tripathi N, Govindarajan A, Zengin ZB, Phillip EJ, et al. Genomic and clinical prognostic factors in patients with advanced urothelial carcinoma receiving immune checkpoint inhibitors. Clin Genitourin Cancer. 2023;21(1):69\u201375. https:\/\/doi.org\/10.1016\/j.clgc.2022.11.007.","journal-title":"Clin Genitourin Cancer"},{"key":"4560_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113368","volume":"195","author":"C Helal","year":"2023","unstructured":"Helal C, Pobel C, Bayle A, Vasseur D, Nicotra C, Blanc-Durand F, et al. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer. Eur J Cancer. 2023;195:113368. https:\/\/doi.org\/10.1016\/j.ejca.2023.113368.","journal-title":"Eur J Cancer"},{"issue":"18","key":"4560_CR16","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1158\/1078-0432.CCR-22-0437","volume":"28","author":"B Szabados","year":"2022","unstructured":"Szabados B, Ponz-Sarvis\u00e9 M, Machado R, Saldana D, Kadel EE, Banchereau R, et al. Clinico-genomic characterization of patients with metastatic urothelial carcinoma in real-world practice identifies a novel bladder immune performance index (BIPI). Clin Cancer Res. 2022;28(18):4083\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0437.","journal-title":"Clin Cancer Res"},{"key":"4560_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4560_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials"},{"issue":"3","key":"4560_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"issue":"11","key":"4560_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"key":"4560_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4560_CR22","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses","author":"GA Wells","year":"2014","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. Ottawa: University of Ottawa; 2014."},{"issue":"7109","key":"4560_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"issue":"10","key":"4560_CR24","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JAC Sterne","year":"2001","unstructured":"Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046\u201355. https:\/\/doi.org\/10.1016\/S0895-4356(01)00377-8.","journal-title":"J Clin Epidemiol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04560-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04560-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04560-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:30:07Z","timestamp":1788967807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04560-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":24,"alternative-id":["4560"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04560-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this study as it was a systematic review and meta-analysis of previously published studies using aggregate data. Consent to participate was not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}